[Form 4] ANEW MEDICAL, INC. Common Stock Insider Trading Activity

Rhea-AI Filing Summary

Klotho Neurosciences director Riad El-Dada reported the acquisition of 10,000 non-qualified stock options on 08/07/2025 with an exercise price of $0.41. The options are stated to be fully vested and exercisable immediately and carry an expiration date of 01/16/2035. After this transaction, the reporting person beneficially owns 40,000 derivative securities related to common stock, held directly.

The Form 4 discloses only this option acquisition and the immediate exercisability; no cash exercises, sales, or other transactions are reported in the filing.

Positive

• 10,000 non-qualified stock options acquired (reported)
• Options carry a $0.41 exercise price and expire on 01/16/2035
• Options are fully vested and exercisable immediately
• Direct beneficial ownership after the transaction is reported as 40,000

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received 10,000 fully vested options at $0.41, raising direct derivative holdings to 40,000 — routine insider award.

The reported grant of 10,000 non-qualified stock options at a $0.41 strike price, exercisable immediately, increases the reporting person’s direct beneficial position to 40,000 underlying shares. This filing documents an insider compensation event rather than a resale or exercise; it does not show cash proceeds or disposition activity. For valuation impact, the filing provides the strike and expiration (01/16/2035) but not the company’s outstanding share count, so potential dilution cannot be quantified from this form alone.

Corporate Governance Expert

TL;DR: Fully vested, immediately exercisable options granted to a director; routine governance disclosure with limited additional detail.

The Form 4 confirms the director status of Riad El-Dada and records a grant of 10,000 options that are fully vested and held directly. Immediate vesting reduces timing-based alignment concerns but also means no future service-based vesting conditions are disclosed. The filing is narrowly focused on the option award and does not indicate any related-party arrangements beyond the standard disclosure fields.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

El-Dada Riad Hussein

(Last) (First) (Middle)

1300 SOUTH BOULEVARD SUITE D

(Street)

CHARLOTTE NC 28203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Klotho Neurosciences, Inc. [ KLTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$0.41	08/07/2025		A		10,000		(1)	01/16/2035	Common Stock	10,000	$0.41	40,000	D

Explanation of Responses:

1. Options are fully vested and can be exercised at any time.

Remarks:

	Riad El-Dada	08/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Riad El-Dada report on the Form 4 for Klotho Neurosciences (KLTO)?

He acquired 10,000 non-qualified stock options on 08/07/2025 at a $0.41 exercise price; options are fully vested and exercisable; expiration 01/16/2035; beneficial ownership after the transaction is 40,000.

How many KLTO derivative securities does Riad El-Dada own after this transaction?

The filing reports 40,000 derivative securities beneficially owned, held directly.

Are the granted options exercisable immediately according to the Form 4?

Yes. The Form 4 states the options are fully vested and can be exercised at any time.

What is the exercise price and expiration date of the options reported on KLTO Form 4?

The exercise price is $0.41 and the expiration date is 01/16/2035.

What is Riad El-Dada's relationship to Klotho Neurosciences (KLTO)?

The Form 4 identifies Riad El-Dada as a Director of the issuer.